Studies on crystalluria in calcium oxalate stone formers.
The excretion of calcium oxalate and calcium phosphate crystals was studied in fractionated 24 h urine from 7 men with recurrent calcium oxalate stone disease, both before and during daily administration of 5 mg bendroflumethiazide. Urinary calcium, oxalate, magnesium, citrate, phosphate, pH, and inhibition of calcium oxalate crystal growth rate were analyzed in all samples. Exclusively calcium oxalate crystals were found in 30 per cent of the samples, all with a pH below 6.25, whereas calcium phosphate was the crystal type encountered in urine with a pH above 6.50. Bendroflumethiazide decreased the volume of calcium phosphate but not of calcium oxalate crystals. During the period of observation there was no correlation between calcium oxalate supersaturation and calcium oxalate crystal volume, but a relationship was demonstrated between calcium phosphate supersaturation and calcium phosphate crystal volume.
D000328:Adult; D000368:Aged; D001539:Bendroflumethiazide / Q000627:therapeutic use; D002129:Calcium Oxalate / Q000652:urine*; D002130:Calcium Phosphates / Q000652:urine*; D002940:Circadian Rhythm; D003460:Crystallization; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007669:Kidney Calculi / Q000188:drug therapy / Q000652:urine*; D008297:Male; D008875:Middle Aged
D002130:Calcium Phosphates; D002129:Calcium Oxalate; D001539:Bendroflumethiazide